OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Yuma Therapeutics Corporation

3 Projects | 1 Researchers | $980,951 Invested

2016

Yuma Therapeutics Corporation

Yukari Perrella

IND-enabling program and Phase 1 clinical trial for Yuma Therapeutics' novel and proprietary lead Hsp90 inhibitor, YT-83, for the treatment of Alzheimer's disease

  • Funding Amount: $556,174
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Proteostasis
  • Status: Closed

2013

Yuma Therapeutics Corporation

Yukari Perrella

The effect of novel heat shock protein 90 (Hsp90) inhibitors on total and phosphorylated tau levels in cerebrospinal fluid and memory deficits in the hTAU441 (tauopathy) mouse transgenic model of Alzheimer's disease

  • Funding Amount: $174,967
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed

2011

Yuma Therapeutics Corporation

Yukari Perrella

Hsp90 Inhibitors for Alzheimer's Disease

  • Funding Amount: $249,810
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed